Physician profile

Paul B Brasher

Pulmonary Disease · Owensboro, KY

NPI 1912341264

$6,564.33

in general payments reported to CMS, 2019-2025

36 companies · $713 in 2025

The $713 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,956.13
Education$779.84
Travel and Lodging$773.86
Gift$101.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $1,778.42 2023-2024 Da Vinci Surgical System
Glaxosmithkline, LLC. $976.76 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Astrazeneca Pharmaceuticals LP $527.02 2019-2025 Fasenra, Breztri, Airsupra
Actelion Pharmaceuticals US, INC. $451.46 2019-2025 Uptravi, Opsumit
Insmed, INC. $332.12 2020-2025 Arikayce
Boehringer Ingelheim Pharmaceuticals, INC. $313.16 2019-2025 Ofev
Olympus America INC. $200.70 2023-2025 Spiration Valve System, Spin Thoracic Navigation System, 120v, 60hz
Electromed, INC. $188.41 2019-2024 Smartvest
United Therapeutics Corporation $182.73 2022-2025 Tyvaso, Tyvaso
Regeneron Healthcare Solutions, INC. $144.31 2021-2025 Dupixent
Amgen INC. $127.80 2022-2025 Tezspire
Baxter Healthcare $116.53 2022-2025 Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System
Genzyme Corporation $114.22 2019-2024
Sunovion Pharmaceuticals INC. $110.59 2019-2020
Mylan Specialty L.P. $97.65 2019-2024 Yupelri
Show all 36 companies
CompanyGeneral paymentsYearsTop products
Jazz Pharmaceuticals INC. $95.60 2019-2024 Xywav
Livanova USA, INC. $90.51 2023 Lifesparc
Grifols USA, LLC $88.90 2019-2025 Prolastin-C Liquid
Gilead Sciences, INC. $70.74 2022-2024 Veklury
Mayne Pharma Commercial LLC $68.17 2019-2020
Harmony Biosciences LLC $67.47 2022-2024 Wakix
Bayer Healthcare Pharmaceuticals INC. $61.72 2025
Philips North America LLC $61.10 2023-2024 (Ak6) Vest Therapy
Merck Sharp & Dohme LLC $57.72 2020-2025 Zerbaxa, Recarbrio, Capvaxive
Teva Pharmaceuticals USA, INC. $56.78 2020-2022
Takeda Pharmaceuticals U.S.A., INC. $25.40 2025 Cuvitru
Mallinckrodt Hospital Products INC. $23.70 2023 Acthar
Teleflex LLC $20.27 2024 Arrow
Pulmonx Corporation $17.75 2021
Avadel Cns Pharmaceuticals, LLC $15.60 2025 Lumryz
Bard Peripheral Vascular, INC. $15.53 2023
Siemens Medical Solutions USA, INC. $14.39 2024 Cios Spin
Viatris Specialty LLC $14.16 2025 Yupelri
Genentech USA, INC. $13.34 2021
Axsome Therapeutics, INC. $11.91 2022
Advanced Respiratory, INC $11.69 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Paul B Brasher

$6,564.33

in general payments reported 2019-2025

Years
2019-2025
Top company
Intuitive Surgical, INC.
Context
The $713 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/1497890/paul-b-brasher

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.